Fig. 1.

Comparison of prevalence and distribution of ESR1 mutations in the IDC and ILC metastatic disease. a Frequency of the different ESR1 mutations in IDC and ILC in the metastases from the MSKCC-IMPACT cohort. b Distribution of the different types of metastases sequenced from IDC and ILC patients, and proportion of the ESR1-mutated (mut) and wild-type (WT) metastases in the MSKCC-IMPACT cohort. c Co-occurrence of ESR1 mutations with GATA3 and FOXA1 mutations in IDC and ILC patients in the MSKCC-IMPACT cohort. d Frequency of the different ESR1 mutations in IDC and ILC in ctDNA from the SoFEA and PALOMA-3 trials